Psychedelic Assisted Therapy with Dr. Alana Roy of Mind Medicine Australia

Over 2018 to 2019 the US Food and Drug Administration (FDA) designated psilocybin (one of key ingredients in psychoactive mushrooms) and MDMA (one of the key ingredients in ecstasy) with “breakthrough status” given the huge promise they’ve both shown in the first stages of clinical trials. Psilocybin showed incredible promise for Major Depressive Disorder (something affecting up to 15% of people living in developed countries at some point in their life). MDMA showed significant promise for Post Traumatic Stress Syndrome. One of the most curious things about the proposed therapies are that they’re once-off or just a few dosed sessions that could cause lifelong changes unlike existing antidepressant medication.